Home | Breaking Out | AI powered stock trade ideas | Bullish Engulfing | Market Signals | New Green Signal Stocks | Recent Red Arrow Top Signals | Recent Green Arrow Bottom Signals | Near Term Bottom Signals | Green Stocks with Most Upside to Analyst Target Price | New Long Term Green AI Signals | Big Tech Stocks | ETF Sector SPDRs | Solar Stocks | Chip Stocks | Airline Stocks | Social Media Stocks | Oil Stocks| Discount Store Stocks | Entertainment Stocks | EV Stocks | Restaurant Stocks | Heavy Equipment Stocks | Aerospace Stocks | Home Builders | Bank Stock Signals | Cruise Ship Stock Signals | Mining Stocks | Free AI Portfolio Analyzer | How to Read and Trade AI Powered Stock Charts| Stock Charts AI top 50 Stocks

Recently Featured Stock Charts
86% AI Stock Prediction Accuracy
Enter Stock Symbol to View AI powered Stock Chart


All Chart Prices Delayed at least 15 minutes

Before accessing this site, you agree that you have read and agree to the disclaimers at the bottom of this page.

Stock Charts AI Power Rank: 0.8
Power Rank trend -> Falling

Last Price: 113.77 - Change: 1.11 - Change %: 0.9853
07/11/2024 16:43:00 EST

DexCom Inc (DXCM)

Industry: Medical Devices

Price Support Resistance

In the past 20 trading days, DXCM has been trading in a range between $117.20 and $110.31 (gray range band). Red lines on the chart represent key resistance levels and Green lines represent key support levels. As the price moves above the lines you will notice they turn green and red if price moves below a line.

The AI powered stock chart is in a Red zone currently. We would avoid this stock.

Upside / Downside Potential

DexCom Inc $DXCM entered a Red zone 33 days ago on the AI powered stock chart. Wall Street analysts have an AVG target price $137, a potential upside of 21.6% from the recent price of 112.66. The stock is trading 26.04% (potential upside) below its 52 week high of $142.00 and 50.72 % (potential downside) above its 52 week low of $74.75 - based on the recent price.

Company Summary

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers.

DXCM Website


Top 4 Must-Have Healthcare Stocks for Long-Term Growth
The healthcare industry represents a substantial and dynamic market sector, presenting many opportunities for investors seeking long-term growth and stability. Factors such as the aging population, technological advances, and rising healthcare costs provide the sector with a compelling combination of growth potential and resilience.
Source: MarketBeat
Thu, 11 Jul 2024 11:11:12 -0400
Sentiment: Positive
DexCom (DXCM), Abbott to Launch First FDA Cleared OTC CGMs
Dexcom (DXCM) and Abbott are set to launch their first FDA-approved over-the-counter CGMs, Stelo and Lingo & Libre Rio, respectively, in the United States this summer.
Source: Zacks Investment Research
Fri, 05 Jul 2024 12:55:44 -0400
Sentiment: Positive
2 Top Growth Stocks to Buy With $1,000
E-commerce powerhouse Shopify has a solid moat and plenty of room to run. DexCom's massive addressable market bodes well for its long-term prospects.
Source: The Motley Fool
Thu, 04 Jul 2024 10:00:00 -0400
Sentiment: Positive
DexCom's ADA Conference Takeaways: Stelo, CGM Tailwinds Still Intact
DexCom presented outlook on diabetes market at the ADA Conference, highlighting potential for growth with new products like Stelo and DexCom ONE. DexCom's strategy differs from Abbott Labs, focusing on OTC CGM products like Stelo to expand target market and drive sales. Despite slight downgrade in outlook for FY24, DexCom's stock positioned for robust sales ramp in second half of the year, with potential for +20% upside.
Source: Seeking Alpha
Wed, 03 Jul 2024 11:27:26 -0400
Sentiment: Positive
Dexcom Schedules Second Quarter 2024 Earnings Release and Conference Call for July 25, 2024 at 4:30 p.m. Eastern Time.
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2024 financial results after market close on Thursday, July 25, 2024. Management will hold a conference call to review the company's second quarter 2024 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will.
Source: Business Wire
Thu, 27 Jun 2024 08:30:00 -0400
Sentiment: Neutral
Instituions Institution %: 97.278
Last QTR Institution change: 3083310

Insiders %: 0.366
Insiders Purchases last QTR: 0
Insiders Sales last QTR: 241994
Insiders Net last QTR: -241994

Analyst Ratings
Target Price: 137
Overall Rating: 4.44
Strong Buys (5): 16
Buys (4): 5
Holds (3): 3
Sells (2): 1
Strong Sells (1): 0

52 Week Hi: 142
52 Week Low: 74.75
Beta: 1.158
50 Day MA: 120.5834
200 Day MA: 116.9674

Earnings / Revenue Trends
Qtr Earnings Growth YOY: 1.987
Qtr Revenue Growth YOY: 0.242
Forward PE: 77.5194
Trailing PE: 73.1558

Benefits of StockChartsAI.com System:

  • Get a Daily List of Stocks Starting New Trends
  • Upload Your Stocks to Quickly See and Track Signals
  • Easy to Understand AI Stock Signals
  • Analysis of Historical Signal Trend Analysis for each stock
  • Search/View AI Stock Signals of Russel 1000 Stocks
  • Easy to Understand AI Stock Signals
  • And MUCH MUCH more!


Stock Analyzed Each Night


Easily Upload Track Your Stocks


See Lists of Stocks Starting New Trends

The information contained on this website is solely for educational purposes, and does not constitute investment advice. The risk of trading in securities markets can be substantial. By accessing this site, you agree we are not liable, whether in contract, tort (including negligence) or otherwise, in respect of any damage, expense or other loss you may suffer arising out of such information or any reliance you may place upon such information from this site. Stocks, Futures and options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the stock, futures and options markets. Don't trade with money you can't afford to lose. This website is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this website. The past performance of any trading system or methodology is not necessarily indicative of future results. Individual results may vary, and testimonials are not claimed to represent typical results. All testimonials are by real people, and may not reflect the typical purchaser’s experience, and are not intended to represent or guarantee that anyone will achieve the same or similar results. HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY, SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.